Product Datasheet

HIF-2 alpha/EPAS1 Antibody (ep190b) NB100-132SS

Unit Size: 0.025 ml

Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Reviews: 9 Publications: 194

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NB100-132

Updated 4/13/2025 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NB100-132



NB100-132SS

HIF-2 alpha/EPAS1 Antibody (ep190b)

| Product Information | | |
|-----------------------------|---|--|
| Unit Size | 0.025 ml | |
| Concentration | 1.0 mg/ml | |
| Storage | Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles. | |
| Clonality | Monoclonal | |
| Clone | ep190b | |
| Preservative | 0.05% Sodium Azide | |
| Isotype | IgG1 | |
| Purity | Protein G purified | |
| Buffer | PBS, 1% BSA | |
| Target Molecular Weight | 96.5 kDa | |
| Product Description | | |
| Host | Mouse | |
| Gene ID | 2034 | |
| Gene Symbol | EPAS1 | |
| Species | Human, Mouse, Rat, Bovine, Hamster | |
| Reactivity Notes | Ability to use HIF-2 alpha/EPAS1 Antibody (ep190b) in mouse is mixed with some positive and some negative results. Use in Bovine reported in scientific literature (PMID:32054096). | |
| Specificity/Sensitivity | This HIF-2 alpha/EPAS1 Antibody (ep190b) is specific for HIF-2 alpha/EPAS1, and does not cross-react with HIF-1 alpha. | |
| Immunogen | The immunogen recognized by this HIF-2 alpha/EPAS1 Antibody (ep190b) maps to a region between amino acids 535-631. [UniProt# Q99814] | |
| Product Application Details | | |
| Applications | Western Blot, Simple Western, ELISA, Flow Cytometry, Gel Super Shift Assays, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin, In vivo assay, Immunoprecipitation, Chromatin Immunoprecipitation (ChIP), Gel Supershift Assay, Knockdown Validated | |
| Recommended Dilutions | Western Blot 1 - 2 ug/mL, Simple Western 1:100, Flow Cytometry 1:400, ELISA 1:100-1:2000, Immunohistochemistry 1:150 - 1:300, Immunocytochemistry/ Immunofluorescence, Immunoprecipitation, Immunohistochemistry-Paraffin 1:150 - 1:300, Immunohistochemistry-Frozen reported in scientific literature (PMID 24973414), Gel Super Shift Assays reported in scientific literature (PMID 17404621), In vivo assay reported in scientific literature (PMID 23857308), Gel Supershift Assay, Chromatin Immunoprecipitation (ChIP), Knockdown Validated reported in scientific literature (PMID 32054096) | |

www.novusbio.com



| Application Notes | In WB, it recognizes a band at approx. 118 kDa representing HIF-2 alpha. |
|-------------------|--|
| | In Simple Western only 10 - 15 uL of the recommended dilution is used per data point. |
| | See <u>Simple Western Antibody Database</u> for Simple Western validation: Tested in Hypoxic HeLa lysate 0.5 mg/mL, separated by Size, antibody dilution of 1:100, apparent MW was 137 kDa. Separated by Size-Wes, Sally Sue/Peggy Sue. The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |

Images









Page 4 of 16 v.20.1 Updated 4/13/2025

| Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - [HRP] [NB100-132H] - Analysis of HIF-2 alpha stabilization over time in HOS cells following exposure to hypoxia. Image using the HRP form of this antibody (NB100-132H). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23785417/) licensed under a CC-BY license. | Hypoxia Norm 15 min 1H 24H 48H 72H HIF-2α 100 kDa |
|--|--|
| Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Western blot analysis and quantification of HIF-2 alpha expression in the cortex 4.5 hours after lipopolysaccharide (LPS) administration for all LPS groups and the control group (SHAM, white bar). With the exception of the vagotomy group (VGX LPS, gray bar), no significant differences to the SHAM group were found in the LPS-treated and sham-operated (SHAM+LPS, light gray bar) or vagus nerve-stimulated groups (VGX LPS+STIM, black bar). The significant increase in the VGX LPS (gray bar) group is an indicator of a hypoxic condition; * P<0.05 compared to SHAM; n=6 rats each. Data are given as the mean+/-SEM. Image collected and cropped by CiteAb from the following publication (https://jneuroinflammation.biomedcentral.com/articles/10.1186/1742- 2094-9-183), licensed under a CC-BY license. | HIF 2 α Actin LPS SHAM SHAM VGX VGX+STIM 0.16 0.14 0.12 0.1 0.08 0.06 0.04 0.02 0 LPS SHA SHA VGX VGX+STIM LPS + + + + + + + + + + + + + + + + + + + |
| Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - 4- OOHCPA exposure induced HIF-2 alpha/EPAS1. A: Western blot analysis of HIF-2 alpha/EPAS1 protein (118KD) and actin (43KD) in limbs at 10 min, 1, 3, 6, and 24 h after treatment with 4-OOHCPA at 0.3 ug/mL (L) 1.0 ug/mL (M) or 3.0 ug/mL (H). P represents the positive control. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0051937), licensed under a CC-BY license. | A HIF2A Actin GLMHGLMHCLMHCLMHCLMHP 10 min 1 h 3 h 6 h 24 h -120 KD -120 KD -43 KD -43 KD |
| Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100- 132] - Analysis of HIF-2 alpha in human endometrium using. Donkey anti-mouse Alexa Fluor 488 secondary antibody was used. IHC image submitted by a verified customer review. | |



С Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] -Functional role of HIF2A in the transcriptional regulation of amphiregulin shControl shHIF1a shHIF2a (AREG) in human cardiac myocytes. Immunoblot for HIF1A or HIF2A from shRNA-transfected normoxic or hypoxic HCM. Beta-Actin (ACTb) Nx Hx Nx Hx Nx Hx (kDa) served as a loading control. Image collected and cropped by CiteAb from HIF1-alpha 100 the following publication (//pubmed.ncbi.nlm.nih.gov/29483579/) licensed 50 under a CC-BY license. ACTb HIF2-alpha ACTb Immunohistochemistry-Paraffin: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - HIF-1a & HIF-2a IHC signals in hypoxic areas of transgenic mouse mammary tumours.A, C Hypoxyprobe (Hyp.pr.) allows visualisation of hypoxic tumour areas. B. Hypoxic peri-necrotic HIF-1α-positive cells display nuclear staining. D. HIF-2α-positive cells show cytoplasmic staining with or without appreciable nuclear staining. * necrosis. E, F. IHC staining for HIF-1 α on MCF-7 breast cancer cells grown under control (E) & hypoxic (F) conditions respectively. G, H. Control (G) & hypoxic (H) MCF-7 cells IHC stained for HIF-2a. 20x obj. Insets show magnification of the boxed area. Size bars 50 µm. Image collected & cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0125771), licensed under a CC-BY license. Not internally tested by Novus Biologicals. Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - HIF-2α expression in the involuting mammary gland. Inserts are enlargements of the indicated areas. Size bars: 50 µm, 40x obj was used in all micrographs. A. In the early involuting gland, the morphology resembles the lactating gland & the basement membrane is evident at this stage. B-D. As tissue remodelling proceeds during involution, the collagen layer becomes unstructured. E-H. HIF-2q-positive cells were detected at all studied stages of involution. I-L. Macrophage infiltration (F4/80 positive) was first evident at the fifth day of involution (J) & increased with time (K, L). Image collected & cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0125771), licensed under a CC-BY license. Not internally tested by Novus Biologicals. Α Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] -ShRNA2 ShRNA2 ShRNA1 Oxygen concentration-dependence of dioxygenase inhibition. A. HIF1 α , HIF2a, & H3K9me2 abundance by western blotting in shRNA1 & shRNA2 cells incubated in 21%, 10%, or 2% oxygen for 72 h. Actin & total H3 serve as loading controls, B, HIF1g, HIF2g, & H3K9me2 HIF1a abundance by western blotting in SDHC knockout iMEFs incubated in H3K9me2 21%, 10%, or 2% oxygen for 72 h. iMEFs were treated with 1 µM TAM H₃ for 7 d prior to analysis. (C-D) Rescue of succinate inhibition of JMHD & PHD inhibition using 0.25 mM octyl- α -ketoglutarate (octyl- α -KG) in Actin SDHB knockdown HEK293 cells & SDHC knockout mouse iMEFs. HIF2a Image collected & cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0127471), licensed under a Actin CC-BY license. Not internally tested by Novus Biologicals. 21% 0, 10% O2 2% 0,



Immunohistochemistry-Paraffin: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Lactating mammary gland.Smaller panels display enlargements of the indicated areas. Size bars: 50 μ m, 40x obj was used for all micrographs. A. Collagen I IHC allows visualisation of the basement membrane surrounding the dilated ducts. B. HIF-1 α was not detected in the epithelial cells of the lactating gland (compare with Fig 1). C. Macrophage infiltration was sparse in the lactating mammary gland as judged by F4/80 IHC. D. A subset of cuboidal luminal epithelial cells was distinctively positive for HIF-2 α . E. The percentage of HIF-2 α -positive out of total luminal epithelial cells was counted in sections from three mice. Image collected & cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0125771), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Mainly CK14-positive, but not CK8-positive, mammary epithelial cells are HIF-2 α positive at day 14 post weaning.Left panels 20x & right 40x objective. Size bars 50 µm. a, A, b & B. Double IHC for HIF-2 α (green) & CK8 (a, A) & CK14 (b, B), respectively (red), reveal that few (if any) CK8-positive luminal cells are HIF-2 α positive. Numerous CK14expressing cells, which include basal & stem/progenitor cells, were positive for HIF-2 α . c, C. F4/80 IHC was performed on an adjacent tissue section detect macrophages. Image collected & cropped by CiteAb from the following publication

(https://dx.plos.org/10.1371/journal.pone.0125771), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Renal tubule specific models of VhI deletion.(A) PCR analysis of recombination at the VhI locus in the kidneys of mice with combinations of Pax8-CreERT2, Slc22a6-CreERT2 & the VhI floxed (fl) & wild-type (+) alleles. The positions of the bands representing the VhI floxed, wild type (Wt) & recombined (Δ) alleles are indicated. (B) Histological images of representative renal sections from 12 month old control, Pax8-CreERT2/VhI Δ/Δ & Slc22a6-CreERT2/VhI Δ/Δ mice (stains & antibodies as indicated, arrowheads indicate abnormal vascularisation). Scale bars, 100µm. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26866916), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry-Paraffin: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - HIF1 α & H3K9me2 accumulation & 5-hydroxy-methyl-2'-deoxycytidine (5hmdC) depletion in PGL specimens compared to controls.Normal ganglia 1 (NG1), normal ganglia 2 (NG2) & IDH-mutant (IDH). Sporadic PGL (Spo. PGL). A. HIF1 α staining. B. HIF2 α staining. C. H3K9me2 staining. Arrows indicate H3K9me2 staining in nuclei of neurons or chief cells. D. 5hmdC staining. Arrows indicate 5hmdC staining in the nuclei of neurons & chief cells. Image collected & cropped by CiteAb from the following publication

(https://dx.plos.org/10.1371/journal.pone.0127471), licensed under a CC-BY license. Not internally tested by Novus Biologicals.





www.novusbio.com

1 h 3 h 6 h 24 h Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - Localization of HIF2A immunoreactivity in limbs. HIF-2A reactivity Control was detected in control limbs at 1 & 3 h in the apical ectodermal ridge, interdigital area (I.R.) & developing cartilaginous anlagen (Digits). 4-OOHCPA exposure increased HIF2A immunoreactivity in the apical ectodermal ridge & interdigital regions (I.R.) at 3 h. No differences were 4-OOHCP 1 µg/ml observed between control & drug-treated limbs after 6 h or 24 h of culture. Four separate replicates were done. Image collected & cropped by CiteAb from the following publication 4-OOHCP/ 3 µg/m (https://dx.plos.org/10.1371/journal.pone.0051937), licensed under a CC-BY license. Not internally tested by Novus Biologicals. Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] -LY2 MCF7 BT474 T47D ZR75B CAMA-1 MPE600 M175 M361 H1428 N H NH N H N H N H N H N H Hypoxic repression of ER- α is dependent on HIF-1 α . a Representative N H N H N H western blots of HIF-1α, HIF-2α & β-actin protein in ten ER-positive cell lines grown at normoxia or hypoxia (1% O2, 24 h). b qPCR analysis of HIF1A mRNA levels in MCF7, BT474, T47D & ZR75B transfected with shScramble or shHIF1A. Relative HIF1A mRNA levels normalized to TBP. (Change in HIF1A levels: *p < 0.0001 MCF7, *p = 0.012 BT474, *p < 0.0001 T47D, *p = 0.0046 ZR75B). c Representative western blots of HIF-1α, ER-α & β-actin protein from MCF7, BT474, T47D & ZR75B with either shScramble or shHIF1A at normoxia & hypoxia (1% O2, 24 h). β-actin is used as a loading control. d Representative western blot of HIF-1α, ER-α & β-actin protein from MCF7, BT474, T47D & ZR75B with or without the transfection of stabilized HIF-1 α (HIF-1 α ODD) Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28320353), licensed under a CC-BY license. Not internally tested by Novus Biologicals. 30 days 70 days Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100a 132] - HIF-1α & HIF-2α expression in the virgin mammary gland.A. Virgin 2 mammary glands (30 & 70 days old) showed no conspicuous basal Collagen membrane, as visualised by collagen IV IHC (a, b). There was also no detectable expression of HIF-2 α in the epithelial cells (c, d). Macrophages (F4/80 positive) were few. In panel c, a single HIF-2α-positive cell was detected, & the adjacent F4/80 IHC section (e) d suggested that this cell is a macrophage. B. Expression of HIF-1 α in mammary epithelium in the 70-day-old virgin mouse. Top panel, IF-2α orientation slide with haematoxylin (HTX) staining, 20x obj. *lymph node. Panels b, d, f. Cross-section of a developing duct close to the invading tip at a stage where the lumen is not yet evacuated, 40x obj. Panels c, e, g. Cross-section of a less mature part of a duct, 40x obj. CK14expressing cells (marker of basal mammary epithelial cells) can be seen in more than one cell layer (panels b & c, arrow-head). At this stage, the lumen is evacuated, but there is still more than one layer of epithelial cells. HIF-1 α IHC on the adjacent sections (panels d, e) showing nuclear F4 expression in non-basal epithelial cells (highlighted by red arrows). Basal (CK14 positive) epithelial cells did not express HIF-1α (black arrows). Mammary epithelial expression of HIF-2a was not detected at these developmental stages. Size bars: 50 µm. Image collected & cropped by CiteAb from the following publication

(https://dx.plos.org/10.1371/journal.pone.0125771), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] -HIF2a inhibitor 76 suppressed CoCl2-induced immature phenotypic characteristics of BCSCs(A) The inhibitory effect of small molecule HIF2 α inhibitor 76 for 24h (10 μ M for 4T1 cells; 25 μ M for Hs578T cells) on CoCl2-induced expression of HIF2α was assessed in both 4T1 & Hs578T cells by western blot analysis. (B) HIF2α inhibitor 76 inhibited primary (with HIF2α inhibitor 76 daily treatment) & second sphere formation (without additional HIF2 α inhibitor 76 treatment) in both 4T1 & Hs578T cells. The sizes of spheres greater than 100 µm were enumerated, with a representative image of a tumor-sphere shown. The data represents an average of three independent experiments. (C) Treatment of 4T1 & Hs578T cells with HIF2a inhibitor 76 for 24 h led to a decrease in the percentage of CD44+/CD24-positive cells as a proportion of total cancer cells. (D) 4T1 & Hs578T cells treated with CoCl2 (100 μ M) for 24h & HIF2 α inhibitor 76 for 24h (10 μ M for 4T1 cells; 25 µM for Hs578T cells) either alone or together were evaluated for the expression levels of stem cell markers c-Myc, Klf4, Oct4, & Nanog by Real-time PCR. Abbreviations: TSFE, Tumor sphere-forming efficiency. β -actin was used as the internal control. The results represent the mean ± SD from three independent experiments. Image collected & cropped by CiteAb from the following publication

(https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.9846), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] -Phd2 deletion leads to activation of the Akt-mTOR pathway. a RPPA analysis of tumors with homozygous deletion of Phd2. Tumor tissues from Tyr::CreER; BRafV600E; Phd2-/- or Tyr::CreER; BRafV600E mice were processed & analyzed by RPPA assays. The analyses identified proteins that were significantly changed in mouse melanomas compared Brafveooe to nevi, b Activation of Akt-mTOR pathway after phd2 deletion. Tumor tissues were processed & western blots showed stabilization of HIF-1 α & HIF-2a proteins after Phd2 depletion. Increased phosphorylation of Akt, 4EBP1 & S6K was observed in tumors from Tyr::CreER; BRafV600E; Phd2-/- compared with those of Tyr::CreER; BRafV600E mice. c Reexpression of Phd2 inhibits the Akt–mTOR pathway. A BRafV600E: Phd2-/- mouse melanoma cell line was established from melanomas in Tyr::CreER; BRafCA; Phd2lox/lox mice. Phd2 was ectopically reintroduced in these tumor cells. Western blot analysis showed that degradation of HIF-1a & HIF-2a proteins with decreased expression of VEGFR2 decreased phosphorylation of Akt, 4EBP1 & S6K. d Pharmacological inhibition (FM19G11) of HIF pathway in BRafV600E; Phd2-/- melanoma cells. A similar but more pronounced inhibition of the Akt–mTOR pathway was observed using the HIF inhibitor. β-Actin was used as a loading control. Results are representative of three independent experiments Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30575721), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Page 8 of 16 v.20.1 Updated 4/13/2025





Page 9 of 16 v.20.1 Updated 4/13/2025





Page 10 of 16 v.20.1 Updated 4/13/2025







Western Blot: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] -Phd2 deletion leads to activation of the Akt–mTOR pathway. a RPPA analysis of tumors with homozygous deletion of Phd2. Tumor tissues from Tyr::CreER; BRafV600E; Phd2-/- or Tyr::CreER; BRafV600E mice were processed & analyzed by RPPA assays. The analyses identified proteins that were significantly changed in mouse melanomas compared to nevi. b Activation of Akt-mTOR pathway after phd2 deletion. Tumor tissues were processed & western blots showed stabilization of HIF-1a & HIF-2α proteins after Phd2 depletion. Increased phosphorylation of Akt. 4EBP1 & S6K was observed in tumors from Tyr::CreER; BRafV600E; Phd2-/- compared with those of Tyr::CreER; BRafV600E mice. c Reexpression of Phd2 inhibits the Akt-mTOR pathway. A BRafV600E; Phd2-/- mouse melanoma cell line was established from melanomas in Tyr::CreER; BRafCA; Phd2lox/lox mice. Phd2 was ectopically reintroduced in these tumor cells. Western blot analysis showed that degradation of HIF-1a & HIF-2a proteins with decreased expression of VEGFR2 decreased phosphorylation of Akt, 4EBP1 & S6K. d Pharmacological inhibition (FM19G11) of HIF pathway in BRafV600E; Phd2-/- melanoma cells. A similar but more pronounced inhibition of the Akt–mTOR pathway was observed using the HIF inhibitor. β-Actin was used as a loading control. Results are representative of three independent experiments Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30575721), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - In-vivo lentiviral delivery of Cre-recombinase to renal tubular epithelium results in recombination of target genes.(a) Diagram of pCCIE lentiviral construct. Cre, Cre-recombinase; IRES, internal ribosome entry site; GFP, Green fluorescent protein. (b) Anti-VHL, HIF1a & GAPDH immunoblots of renal cortical protein lysates from Vhlwt/wt & Vhlfl/fl mice intrarenally injected with CCIE. Samples were collected 12 months post infection with each column representing an individual mouse. Blots were cropped to improve clarity, full-length blots are presented in Supplementary Fig. S3a. (c) Histological images of renal sections from Vhlwt/wt & Vhlfl/fl mice intrarenally injected with CCIE at 12 months post injection (stains & antibodies as indicated). Scale bars, 100 µm. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26046460), licensed under a CC-BY license. Not internally tested by Novus Biologicals.









Immunohistochemistry-Paraffin: HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132] - HIF-1a & HIF-2a expression in the virgin mammary gland.A. Virgin mammary glands (30 & 70 days old) showed no conspicuous basal membrane, as visualised by collagen IV IHC (a, b). There was also no detectable expression of HIF-2α in the epithelial cells (c, d). Macrophages (F4/80 positive) were few. In panel c, a single HIF-2α-positive cell was detected, & the adjacent F4/80 IHC section (e) suggested that this cell is a macrophage. B. Expression of HIF-1 α in mammary epithelium in the 70-day-old virgin mouse. Top panel, orientation slide with haematoxylin (HTX) staining, 20x obj. *lymph node. Panels b, d, f. Cross-section of a developing duct close to the invading tip at a stage where the lumen is not yet evacuated, 40x obj. Panels c, e, g. Cross-section of a less mature part of a duct, 40x obj. CK14expressing cells (marker of basal mammary epithelial cells) can be seen in more than one cell layer (panels b & c, arrow-head). At this stage, the lumen is evacuated, but there is still more than one layer of epithelial cells. HIF-1α IHC on the adjacent sections (panels d, e) showing nuclear expression in non-basal epithelial cells (highlighted by red arrows). Basal (CK14 positive) epithelial cells did not express HIF-1α (black arrows). Mammary epithelial expression of HIF-2a was not detected at these developmental stages. Size bars: 50 µm. Image collected & cropped by CiteAb from the following publication

(https://dx.plos.org/10.1371/journal.pone.0125771), licensed under a CC-BY license. Not internally tested by Novus Biologicals.





Publications

Kling L, Eulenberg-Gustavus C, Jerke U, Rousselle A et Al. ?(2)-integrins control HIF1? activation in human neutrophils Front Immunol 2024-10-29 [PMID: 39469705]

Xia J, Chen H, Wang X et Al. Sphingosine d18:1 promotes nonalcoholic steatohepatitis by inhibiting macrophage HIF-2? Nat Commun 2024-06-04 [PMID: 38834568]

M Koeppen, JW Lee, SW Seo, KS Brodsky, S Kreth, IV Yang, PM Buttrick, T Eckle, HK Eltzschig Hypoxia-inducible factor 2-alpha-dependent induction of amphiregulin dampens myocardial ischemia-reperfusion injury Nat Commun, 2018-02-26;9(1):816. 2018-02-26 [PMID: 29483579]

Liu S, Zhang G, Guo J et al. Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis Nat Commun 2018-12-21 [PMID: 30575721]

Ivan Menendez-Montes, Beatriz Escobar, Manuel J. Gomez, Teresa Albendea-Gomez, Beatriz Palacios, Elena Bonzon-Kulichenko, Jose Luis Izquierdo-Garcia, Ana Vanessa Alonso, Alessia Ferrarini, Luis Jesus Jimenez-Borreguero, Jesus Ruiz-Cabello, Jesus Vázquez, Silvia Martin-Puig Activation of amino acid metabolic program in cardiac HIF1-alpha-deficient mice iScience 2021-02-03 [PMID: 33665549]

R Berggren-N, M Ryde, A Löfdahl, A Ibáñez-Fon, M Kåredal, G Westergren, E Tufvesson, AK Larsson-Ca Effects of hypoxia on bronchial and alveolar epithelial cells linked to pathogenesis in chronic lung disorders Frontiers in Physiology, 2023-03-13;14(0):1094245. 2023-03-13 [PMID: 36994416]

Mallikarjuna P, Raviprakash TS, Aripaka K et al. Interactions between TGF-beta type I receptor and hypoxia-inducible factor-α mediates a synergistic crosstalk leading to poor prognosis for patients with clear cell renal cell carcinoma Cell Cycle 2019-09-01 [PMID: 31339433]

Hyunbum Kim, Yu Liu, Jiwon Kim, Yunhye Kim, Timothy Klouda, Sudeshna Fisch, Seung Han Baek, Tiffany Liu, Suzanne Dahlberg, Cheng-Jun Hu, Wen Tian, Xinguo Jiang, Kosmas Kosmas, Helen A Christou, Benjamin D Korman, Sara O Vargas, Joseph C Wu, Kurt R Stenmark, Vinicio de Jesus Perez, Mark R Nicolls, Benjamin A Raby, Ke Yuan Pericytes contribute to pulmonary vascular remodeling via HIF2α signaling EMBO Reports 2024-01-19 [PMID: 38243138]

Fan Y, Li H, Ma X et al. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2alpha. Oncotarget 2016-04-05 [PMID: 26943772]

Chul Ju Hwang, Mi Hee Park, Jae Yeon Hwang, Ju Hwan Kim, Na Young Yun, Sang Yeon Oh, Ju Kyung Song, Hyun Ok Seo, Yun-Bae Kim, Dae Yeon Hwang, Ki-Wan Oh, Sang-Bae Han, Jin Tae Hong CCR5 deficiency accelerates lipopolysaccharide-induced astrogliosis, amyloid-beta deposit and impaired memory function Oncotarget 2016-03-15 [PMID: 26910914]

Zhou X, Zheng Y, Sun W et al. D-mannose alleviates osteoarthritis progression by inhibiting chondrocyte ferroptosis in a HIF-2?-dependent manner Cell Proliferation 2021-11-01 [PMID: 34561933] (Immunohistochemistry, Western Blot, Immunocytochemistry/ Immunofluorescence)

Garcia JA, Chen R, Xu M et al. Acss2/HIF-2 signaling facilitates colon cancer growth and metastasis PloS one 2023-03-02 [PMID: 36862715] (Immunoprecipitation, Western Blot, Human)

More publications at http://www.novusbio.com/NB100-132



Procedures

Immunohistochemistry Protocol for HIF-2 alpha Antibody (NB100-132)

Monoclonal Anti-HIF-2 alpha Western Blot Procedure

- 1. Resolve nuclear cell extracts (50-100 ug/lane) on a 6% SDS-polyacrylamide gel, under reducing conditions.
- 2. Transfer to a nitrocellulose membrane, overnight, or to a *PVDF membrane [*in 20 mM Tris/100 mM glycine/10% (v/v) methanol/0.05% SDS].
- 3. Block the membrane in TBS containing 5% non-fat dry milk and 0.1% Tween-20.
- 4. Rinse the membrane in TBST, twice.
- 5. Incubate the membrane in anti-HIF-2 alpha (NB 100-132), diluted 1:500 in TBS+1% BSA, overnight at 4C.
- 6. Wash membrane with TBST for 35 minutes at RT (1 X 15 minutes, 2 X 10 minutes).
- 7. Incubate the membrane with diluted HRP conjugated goat anti-mouse antibody.
- 8. Wash membrane with TBST for 35 minutes at RT (1 X 15 minutes, 2 X 10 minutes).
- 9. Use Amersham ECL Kit, as directed, to detect image.

Immunohistochemistry Procedure for Paraffin Sections

1. Prior to performing the IPOX experiment, dewax the paraffin sections by baking them at 60C for 30 minutes and then putting them through citroclear.

- 2. Hydrate the sections through the following series:
- A. 3 X 5 minutes xylenes
- B. 3 X 5 minutes 100% Etoh
- C. 2 minutes 95% Etoh
- D. 2 minutes 70% Etoh
- E. 1 minute 50% Etoh
- F. 1 minute ddH2O
- G. 1 minute TBS
- 3. Block endogenous peroxidase with 0.5% hydrogen peroxide in water, for 30 minutes.

4. Antigen unmasking is performed by incubating at 60C for 16 hours, in 50mmol/L Tris and 0.2 mmol/L EDTA (pH 9.0), using a covered water bath.

- 5. Rinse slides with PBS and then incubate with PBS containing 0.2% Triton X-100 for 10 minutes.
- 6. Rinse slides with PBS.
- 7. Incubate sections with 1:1,000-1:3,000 dilution of anti-HIF-2 alpha (NB 100-132) for 90 minutes at RT.
- 8. Incubate sections in secondary HRP-conjugated goat anti-mouse serum for 30 minutes at RT.
- 9. Incubate sections in tertiary HRP-conjugated rabbit anti-goat serum for 30 minutes at RT.
- 10. Develop the peroxidase reaction using diaminobenzidine.
- 11. Wash slide and mount in aqueous mountant.

Substitution of the primary antibody with PBS can be used as a negative control.

1. Sub-confluent cells are grown on chamber slides and incubated for 16 hours either in air or under 0.1% hypoxia.

- 2. Wash cells in ice-cold PBS.
- 3. Fix cells in formaldehyde (3.7% in PBS) for 10 minutes at room temperature (RT).
- 4. Wash cells twice, in PBS, and permeabilize by incubating in 0.2% Triton X-100 in PBS for 10 minutes at RT.
- 5. Incubate the slides with 1:1,000-1:3,000 dilution of anti-HIF-2 alpha (NB 100-132) for 1 hour at RT.
- 6. Wash in PBS for 5 minutes.
- 7. Incubate with HRP-conjugated goat anti-mouse for 30 minutes at RT.
- 8. Detect binding using 3Prime-diaminobenzidine.
- 9. Counterstain with hematoxylin.
- **IHC-FFPE** sections
- I. Deparaffinization:

A. Treat slides with Xylene: 3 changes for 5 minutes each. Drain slides for 10 seconds between changes.

B. Treat slides with 100% Reagent Alcohol: 3 changes for 5 minutes each. Drain slides for 10 seconds between changes.

- II. Quench Endogenous Peroxidase:
- A. Place slides in peroxidase quenching solution: 15-30 minutes.
- To Prepare 200 ml of Quenching Solution:
- -Add 3 ml of 30% Hydrogen Peroxide to 200 ml of Methanol.



-Use within 4 hours of preparation

B. Place slides in distilled water: 2 changes for 2 minutes each.

III. Retrieve Epitopes:

A. Preheat Citrate Buffer. Place 200 ml of Citrate Buffer Working Solution into container, cover and place into steamer. Heat to 90-96 degrees C.

- B. Place rack of slides into hot Citrate Buffer for 20 minutes. Cover.
- C. Carefully remove container with slides from steamer and cool on bench, uncovered, for 20 minutes.
- D. Slowly add distilled water to further cool for 5 minutes.
- E. Rinse slides with distilled water. 2 changes for 2 minutes each.

IV. Immunostaining Procedure:

A. Remove each slide from rack and circle tissue section with a hydrophobic barrier pen (e.g. Liquid Blocker-Super Pap Pen).

B. Flood slide with Wash Solution.

Do not allow tissue sections to dry for the rest of the procedure.

C. Drain wash solution and apply 4 drops of Blocking Reagent to each slide and incubate for 15 minutes.

D. Drain Blocking Reagent (do not wash off the Blocking Reagent), apply 200 ul of Primary Antibody solution to each slide, and incubate for 1 hour.

E. Wash slides with Wash Solution: 3 changes for 5 minutes each.

F. Drain wash solution, apply 4 drops of Secondary antibody to each slide and incubate for 1 hour.

G. Wash slides with Wash Solution: 3 changes for 5 minutes each.

H. Drain wash solution, apply 4 drops of DAB Substrate to each slide and develop for 5-10 minutes. Check development with microscope.

I. Wash slides with Wash Solution: 3 changes for 5 minutes each.

J. Drain wash solution, apply 4 drops of Hematoxylin to each slide and stain for 1-3 minutes. Increase time if darker counterstaining is desired.

K. Wash slides with Wash Solution: 2-3 changes for 2 minutes each.

L. Drain wash solution and apply 4 drops of Bluing Solution to each slide for 1-2 minutes.

M. Rinse slides in distilled water.

N. Soak slides in 70% reagent alcohol: 3 minutes with intermittent agitation.

O. Soak slides in 95% reagent alcohol: 2 changes for 3 minutes each with intermittent agitation.

P. Soak slides in 100% reagent alcohol: 3 changes for 3 minutes each with intermittent agitation. Drain slides for 10 seconds between each change.

Q. Soak slides in Xylene: 3 changes for 3 minutes each with intermittent agitation. Drain slides for 10 seconds between each change.

R. Apply 2-3 drops of non-aqueous mounting media to each slide and mount coverslip.

S. Lay slides on a flat surface to dry prior to viewing under microscope.

NOTES:

-Use treated slides (e.g. HistoBond) to assure adherence of FFPE sections to slide.

-Prior to deparaffinization, heat slides overnight in a 60 degrees C oven.

-All steps in which Xylene is used should be performed in a fume hood.

For Epitope Retrieval, a microwave or pressure cooker may be substituted for the steamer method. Adjust times as necessary depending on conditions.

-For the initial IHC run with a new primary antibody, test tissues with and without Epitope Retrieval. In some instances, Epitope Retrieval may not be necessary.

-200 ul is the recommended maximum volume to apply to a slide for full coverage. Using more than 200 ul may allow solutions to wick off the slide and create drying artifacts. For small tissue sections less than 200 ul may be used.

-5 minutes of development with DAB Substrate should be sufficient. Do not develop for more than 10 minutes. If 5 minutes of development causes background staining, further dilution of the primary antibody may be necessary. -Hematoxylin should produce a light nuclear counterstain so as not to obscure the DAB staining. Counterstain for 1-1 ½ minutes for nuclear antigens. Counterstain for 2-3 minutes for cytoplasmic and membranous antigens. If darker counterstaining is desired increase time (up to 10 minutes).

www.novusbio.com





Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112 USA Phone: 303.730.1950 Toll Free: 1.888.506.6887 Fax: 303.730.1966 nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave Toronto, ON M8Z 4E6 Canada Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402 canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449 Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com Technical Support: nb-technical@biotechne.com Orders: nb-customerservice@bio-techne.com General: novus@novusbio.com

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NB100-132

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

